New England Journal of Medicine, Ahead of Print.
Risultati per: Nuovi possibili trattamenti per il morbo di Alzheimer
Questo è quello che abbiamo trovato per te
Londra rischia un'epidemia di morbillo, possibili 160 mila casi
Basse coperture dovute anche alla bufala su vaccini e autismo
Emergenza Alzheimer, 700mila malati e 15mld l'anno di costi
80% delle spese sostenute direttamente da pazienti e famiglie
Fda dà il via libera ad un nuovo farmaco contro l'Alzheimer
Riduce il rallentamento cognitivo del 28% in 18 mesi
CMS Will Cover Alzheimer Drugs With Traditional FDA Approval
Alzheimer disease drugs that receive traditional approval from the US Food and Drug Administration (FDA) will be covered under Medicare for patients who qualify for them, the Centers for Medicare & Medicaid Services (CMS) announced.
Association Between False Memories and Delusions in Alzheimer Disease
This cross-sectional study uses behavioral testing and volumetric neuroimaging data to examine the association between false memories and delusions among individuals in the Alzheimer Disease Neuroimaging Initiative cohort.
Brain Cell Biomarker for Preclinical Alzheimer Disease Identified
Astrocytes, cells that are involved in the brain’s support system, might play an important role in the progression of Alzheimer disease, according to results from 1016 participants with and without amyloid-β pathology who were all cognitively unimpaired. Participants were aged 70 years on average.
Microbioma intestinale alterato spia precoce dell'Alzheimer
Possibile una diagnosi più precoce
FDA Greenlights First Drug for Agitation Related to Alzheimer Disease
Brexpiprazole, marketed as Rexulti, was granted supplemental approval on May 11 by the US Food and Drug Administration (FDA) for treating agitation linked with Alzheimer disease, the most common cause of dementia. Approval for the drug is based on results from 2 phase 3 randomized clinical trials that showed “statistically significant and clinically meaningful improvements” in caregiver-reported agitation symptoms for patients receiving 2 or 3 mg of brexpiprazole compared with those receiving a placebo, according to the FDA’s statement.
Aifa, limitare gli antibiotici fluorochinoloni, possibili rischi
Avviso di sicurezza, ancora prescritti fuori da usi raccomandati
New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines—Highlights From the 2023 American Academy of Neurology Conference
This Medical News article discusses research presented at the recent American Academy of Neurology Conference.
Farmaco contro l'Alzheimer rallenta del 35% il declino cognitivo
Eli Lilly, ‘trial su 1.200 persone, chiederemo l’autorizzazione’
Lecanemab in Early Alzheimer’s Disease
New England Journal of Medicine, Volume 388, Issue 17, Page 1630-1632, April 2023.
Covid: studio, possibili relazioni con fattori meteorologici
Ricercatori Unimore, esiste una ‘finestra climatica’ ottimale
Bimba haitiana con il morbo blu sarà salvata al Sant'Orsola
Al via raccolta fondi di Piccoli Grandi Cuori per aiutarla